secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001104659-25-052704
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics granted Nasdaq listing extension to Sept 16, 2025
----------------------------------------------------------------------

- Nasdaq Hearings Panel extended compliance deadline for MVLS Rule (minimum $35M market value for 10 consecutive days) to September 16, 2025.
- Extension is subject to BioXcel meeting certain interim conditions set by the Panel.
- Company previously faced potential delisting for failing to satisfy Nasdaq Listing Rule 5550(b)(2).
- Decision follows review of BioXcel's compliance plan and strategies for long-term compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925052704/0001104659-25-052704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925052704/tm2516117d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer